Pfenex Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock.
The number of shares to be sold and the price range for the proposed offering have not yet been determined, according to a release. Pfenex is a San Diego-based clinical-stage biotechnology company developing and commercializing what are considered difficult-to-manufacture proteins.
William Blair & Company LLC and JMP Securities LLC are acting as joint book-running managers for the offering and Mizuho Securities USA Inc. is acting as a co-manager.
A registration statement relating to the securities has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
Pfenex said the offering will be made only by means of a prospectus.